70/100B285.62
USD
2.01
(0.71%)
Market Open
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 2.91Revenue estimate 26.42B
Q4 FY2026 · Earnings report
EPS estimate 2.91Revenue estimate 26.42B
If you had invested in Johnson & Johnson ago, it would be worth $3,141 today, against $4,096 in SPY and $6,368 in QQQ.
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
70/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation2
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
Johnson & Johnson key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Blend stock · 3.8/10Growth 3.3 · Value 2.2 · Dividend 3.8
- Day range
- 284.09 – 286.41
- 52-week range
- 185.12 – 286.41
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 687.58B USD
- P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 43.30
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 5.31
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- 6.60
- Div YieldWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 1.88%
- EPS growth forecast (FY2026)
- +2.9%
- Volume
- 26,317
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 0.24
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 74.9/100Environment 83 · Social 70 · Governance 73
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato
- Employees
- 142K
- Website
- jnj.com
- IPO date
- 2 Jan 1962
Johnson & Johnson earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q4 FY2026
EPS estimate
2.91 USD
Revenue estimate
26.42B USD
Last quarter · Q3 FY2026
EPS2.59Beat +2.8%Revenue25.40BBeat +0.1%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q1 FY2027 | 2.68 | — | — | -0.77% | 25.50B | — | — | +5.99% | |
| Q4 FY2026 | 2.91 | — | — | +18.29% | 26.42B | — | — | +7.55% | |
| Q3 FY2026 | 2.52 | 2.59 | +2.78% | -7.50% | 25.38B | 25.40B | +0.06% | +5.86% | |
| Q2 FY2026 | 2.85 | 2.90 | +1.75% | +4.69% | 25.06B | 25.31B | +0.99% | +6.60% | |
| Q1 FY2026 | 2.68 | 2.70 | +0.75% | -2.53% | 23.61B | 24.06B | +1.89% | +9.91% | |
| Q4 FY2025 | 2.46 | 2.46 | 0.00% | +20.59% | 24.15B | 24.56B | +1.72% | +9.08% | |
| Q3 FY2025 | 2.76 | 2.80 | +1.45% | +15.70% | 23.76B | 23.99B | +1.00% | +6.77% | |
| Q2 FY2025 | 2.68 | 2.77 | +3.36% | -1.77% | 22.85B | 23.74B | +3.89% | +5.77% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 13.96 | — | — | +20.43% | 116.59B | — | — | +8.19% |
| FY2027 | 11.59 | — | — | +4.27% | 107.76B | — | — | +6.46% |
| FY2026 | 11.11 | — | — | +2.91% | 101.22B | — | — | +7.46% |
| FY2025 | 10.80 | 10.80 | -0.03% | +8.11% | 93.76B | 94.19B | +0.46% | +6.05% |
| FY2024 | 9.95 | 9.99 | +0.41% | -4.22% | 88.78B | 88.82B | +0.05% | +4.30% |
| FY2023 | 10.05 | 10.43 | +3.82% | +2.66% | 95.02B | 85.16B | -10.38% | -6.57% |
| FY2022 | 9.83 | 10.16 | +3.34% | +3.67% | 94.45B | 91.15B | -3.50% | -2.80% |
Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved
Johnson & Johnson analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
285.31 USD
-0.11%
Analysts' 1-year price targets range from 260.00 to 320.00, with an average of 285.31.
Past year
1-year forecast
Strong sellStrong buy
Buy
19 ratings
| Buy | 12 | |
| Hold | 7 | |
| Sell | 0 |
12-month price target
| Highest target | 320.00 |
| Average target | 285.31 |
| Lowest target | 260.00 |
| Current price | 285.62 |
Johnson & Johnson valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 43.30
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 25.70
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 6.92
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 8.43
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 23.21
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
687.58B USD
+
Total debt
44.65B USD
−
Cash and short-term investments
17.23B USD
=
Enterprise value
715.00B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Johnson & Johnson against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: AbbVie, Merck & Co., Eli Lilly and, Amgen, Gilead Sciences, and Pfizer, the US Drug Manufacturers - General companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Highest in 5 years43.39.443.3
- Gross marginLowest in 5 years67.9%67.9%70.3%Against its peers: 7 of 7Peers' median 73.2%
- Operating marginAbove its median27.2%24.9%27.5%Against its peers: 7 of 7Peers' median 34.5%
- Net marginAbove its median28.5%15.8%41.3%Against its peers: 3 of 7Peers' median 24.6%
- Return on equityAbove its median32.9%19.7%51.1%Against its peers: 5 of 6Peers' median 37.5%
- Free cash flow marginLowest in 5 years20.9%20.9%25.1%Against its peers: 4 of 7Peers' median 20.5%
- Revenue growthAbove its median6.0%-4.7%6.5%Against its peers: 4 of 7Peers' median 5.5%
- EPS growthAbove its median90.5%-57.8%103.9%Against its peers: 3 of 7Peers' median 48.1%
- Debt to EBITDALowest in 5 years1.17×1.17×1.49×Against its peers: 1 of 7Peers' median 2.53×
- Current ratioBelow its median1.030.991.35Against its peers: 6 of 7Peers' median 1.35
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Johnson & Johnson growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 99.34B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 16.10B USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 68.81%
- Operating margin
- 25.70%
- Net margin
- 16.20%
Revenue / Net income
Revenue Net income Net margin
Johnson & Johnson revenue breakdown
By product
FY2025
64.1%Innovative Medicine35.9%MedTech
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Innovative Medicine | 60.40B | 64.1% | +6.0% |
| MedTech | 33.79B | 35.9% | +6.1% |
By region
FY2025
57.1%United States22.9%Europe14.9%Asia-Pacific, Africa5.2%Western Hemisphere, excluding U.S.
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| United States | 53.75B | 57.1% | +6.9% |
| Europe | 21.54B | 22.9% | +6.5% |
| Asia-Pacific, Africa | 14.03B | 14.9% | +3.2% |
| Western Hemisphere, excluding U.S. | 4.88B | 5.2% | +3.4% |
How Johnson & Johnson makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Innovative Medicine60.40B 64.1%
MedTech33.79B 35.9%
Revenue94.19B 100.0%
Cost of revenue30.26B 32.1%
Gross profit63.94B 67.9%
Research and development14.67B 15.6%
Selling and administration23.68B 25.1%
Operating income25.60B 27.2%
Tax5.78B 6.1%
Net income26.80B 28.5%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Johnson & Johnson dividendsWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- Annual dividend
- 5.36 USD
- Dividend yield (indicated)What is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 1.88%
- Payout ratioWhat is the payout ratio? The payout ratio is the share of a company's earnings paid out as dividends: dividends per share divided by earnings per share (EPS).
- 100.37%
- Years of dividend growthWhat are years of dividend growth? The years in a row a company has raised its dividend per share. 25 years make an S&P 500 company a Dividend Aristocrat; 50 make a Dividend King.
- 56+
- Frequency
- Quarterly
- Next payment
- 1.34 USD
- Next ex-dividend dateWhat is the ex-dividend date? The ex-dividend date is the first day a stock trades without its next dividend: buy before it to receive the payment; buy on or after it and the seller gets it.
- 24 Nov 2026
- Next payment date
- 8 Dec 2026
Dividends per share
Johnson & Johnson financial health
- Cash and short-term investments
- 17.23B USD
- Total debt
- 44.65B USD
- Net cash
- -27.42B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 20.59B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 1.02
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 0.55
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 7 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 5.56
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Johnson & Johnson ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 74.50%
- Institutional holders
- 4,814 (+47)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 99.88%
Who owns the shares
Institutions 74.5% Others 25.5%
As of 30 Jun 2026
Shares free to trade
Free float 2.40B shares ·99.9% Closely held 2.95M shares ·0.1%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q3 2026 | 0 | 9 | 204.72K | 452.56K |
| Q2 2026 | 0 | 1 | 47.79K | 56.26K |
| Q1 2026 | 0 | 16 | 1.16M | 971.56K |
| Q4 2025 | 1 | 1 | 23.56K | 43.44K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling PrepVerified against SEC filings
Related Instruments
Title: Johnson & Johnson
Sector: Healthcare
Industry: Drug Manufacturers - General
Johnson & Johnson is an American multinational corporation founded in 1886 by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. The company’s ethos is centered around good health as the foundation of vibrant lives. Since its inception, it has continued this mission and is now considered the world’s largest and most broadly based healthcare company, with more than 140,000 employees around the world.
The company develops medical devices, pharmaceuticals, and consumer packaged goods. It features prominently in the top 50 of the Fortune 500 list of corporations by total revenue. The company is headquartered in New Brunswick, New Jersey. Its holdings include some 250 subsidiary companies with operations in 60 countries and products sold in over 175 nations. Among its best-known brand assets are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's Baby products, Neutrogena skin products, and more.